Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001654954-20-001517
Filing Date
2020-02-13
Accepted
2020-02-13 16:36:23
Documents
58
Period of Report
2019-12-31

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT vtgn10q_dec312019.htm 10-Q 2093772
2 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF ex31-1.htm EX-31.1 12499
3 CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF ex31-2.htm EX-31 13427
4 CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE ex32.htm EX-32 7580
  Complete submission text file 0001654954-20-001517.txt   4584236

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT vtgn-20191231.xml EX-101.INS 636284
6 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20191231.xsd EX-101.SCH 31712
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vtgn-20191231_cal.xml EX-101.CAL 43602
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20191231_def.xml EX-101.DEF 100249
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20191231_lab.xml EX-101.LAB 203635
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20191231_pre.xml EX-101.PRE 176285
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
VistaGen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-37761 | Film No.: 20611301
SIC: 2834 Pharmaceutical Preparations